Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Investigating the allosteric reverse signalling of PARP inhibitors with microsecond molecular dynamic simulations and fluorescence anisotropy.

Marchand JR, Carotti A, Passeri D, Filipponi P, Liscio P, Camaioni E, Pellicciari R, Gioiello A, Macchiarulo A.

Biochim Biophys Acta. 2014 Oct;1844(10):1765-72. doi: 10.1016/j.bbapap.2014.07.012.

PMID:
25062913
2.

Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.

Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y.

J Pharmacol Exp Ther. 2014 Jun;349(3):408-16. doi: 10.1124/jpet.113.210146.

3.

Trapping Poly(ADP-Ribose) Polymerase.

Shen Y, Aoyagi-Scharber M, Wang B.

J Pharmacol Exp Ther. 2015 Jun;353(3):446-57. doi: 10.1124/jpet.114.222448.

4.

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.

Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y.

Mol Cancer Ther. 2014 Feb;13(2):433-43. doi: 10.1158/1535-7163.MCT-13-0803.

5.

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.

Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, DiGiammarino EL, Panchal SC, Wilsbacher JL, Gao W, Olson AM, Stolarik DF, Osterling DJ, Johnson EF, Maag D.

Mol Cancer Res. 2015 Nov;13(11):1465-77. doi: 10.1158/1541-7786.MCR-15-0191-T.

6.

Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase.

Moroni F, Cozzi A, Chiarugi A, Formentini L, Camaioni E, Pellegrini-Giampietro DE, Chen Y, Liang S, Zaleska MM, Gonzales C, Wood A, Pellicciari R.

Br J Pharmacol. 2012 Mar;165(5):1487-500. doi: 10.1111/j.1476-5381.2011.01666.x.

7.

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y.

Cancer Res. 2012 Nov 1;72(21):5588-99. doi: 10.1158/0008-5472.CAN-12-2753.

8.

From polypharmacology to target specificity: the case of PARP inhibitors.

Liscio P, Camaioni E, Carotti A, Pellicciari R, Macchiarulo A.

Curr Top Med Chem. 2013;13(23):2939-54. Review.

PMID:
24171773
9.

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.

Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ.

Breast Cancer Res. 2015 Mar 7;17:33. doi: 10.1186/s13058-015-0534-y.

10.

PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.

Peralta-Leal A, Rodríguez-Vargas JM, Aguilar-Quesada R, Rodríguez MI, Linares JL, de Almodóvar MR, Oliver FJ.

Free Radic Biol Med. 2009 Jul 1;47(1):13-26. doi: 10.1016/j.freeradbiomed.2009.04.008. Review.

PMID:
19362586
11.

Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.

Wang B, Qian H, Yiu SM, Sun J, Zhu G.

Eur J Med Chem. 2014 Jan;71:366-73. doi: 10.1016/j.ejmech.2013.10.062.

PMID:
24361480
12.

PARP inhibitors: polypharmacology versus selective inhibition.

Ekblad T, Camaioni E, Schüler H, Macchiarulo A.

FEBS J. 2013 Aug;280(15):3563-75. doi: 10.1111/febs.12298. Review.

13.

Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.

Norris RE, Adamson PC, Nguyen VT, Fox E.

Pediatr Blood Cancer. 2014 Jan;61(1):145-50. doi: 10.1002/pbc.24697.

14.

Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review.

Buege M, Mahajan PB.

Rev Recent Clin Trials. 2015;10(4):326-39. Review.

PMID:
26374559
15.
16.

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH.

Clin Cancer Res. 2012 Mar 15;18(6):1655-62. doi: 10.1158/1078-0432.CCR-11-2890.

17.

Exploring the effect of PARP-1 flexibility in docking studies.

Antolin AA, Carotti A, Nuti R, Hakkaya A, Camaioni E, Mestres J, Pellicciari R, Macchiarulo A.

J Mol Graph Model. 2013 Sep;45:192-201. doi: 10.1016/j.jmgm.2013.08.006.

PMID:
24056306
18.

Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer.

Steffen JD, Tholey RM, Langelier MF, Planck JL, Schiewer MJ, Lal S, Bildzukewicz NA, Yeo CJ, Knudsen KE, Brody JR, Pascal JM.

Cancer Res. 2014 Jan 1;74(1):31-7. doi: 10.1158/0008-5472.CAN-13-1701.

19.

Natural inhibitors of poly(ADP-ribose) polymerase-1.

Banasik M, Stedeford T, Strosznajder RP.

Mol Neurobiol. 2012 Aug;46(1):55-63. doi: 10.1007/s12035-012-8257-x. Review.

PMID:
22476980
20.

Poly(ADP-ribose)polymerase inhibition - where now?

Woon EC, Threadgill MD.

Curr Med Chem. 2005;12(20):2373-92. Review.

PMID:
16181138
Items per page

Supplemental Content

Support Center